Stockscreener 앱 받기
1.53
4.08%
0.06
시간 외 거래:
1.55
0.02
+1.31%
전일 마감가:
$1.47
열려 있는:
$1.48
하루 거래량:
2.69M
Relative Volume:
0.67
시가총액:
$406.01M
수익:
$194.75M
순이익/손실:
$-51.26M
주가수익비율:
-5.4643
EPS:
-0.28
순현금흐름:
$-23.38M
1주 성능:
-4.97%
1개월 성능:
-0.65%
6개월 성능:
-57.85%
1년 성능:
-17.74%
1일 변동 폭
$1.48
$1.565
1주일 범위
$1.46
$1.63
52주 변동 폭
$1.445
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
명칭
Akebia Therapeutics Inc
전화
617-871-2098
주소
245 FIRST STREET, CAMBRIDGE, MA
AKBA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.53 | 390.09M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
125.67 | 57.00B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.90 | 49.88B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.05 | 45.73B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 36.84B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
RGC
Regencell Bioscience Holdings Ltd
|
52.88 | 16.33B | 0 | -5.87M | -767.30K | -0.45 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-04 | 재개 | H.C. Wainwright | Buy |
| 2025-04-28 | 개시 | Leerink Partners | Outperform |
| 2025-04-01 | 개시 | Jefferies | Buy |
| 2023-11-29 | 재개 | BTIG Research | Buy |
| 2023-08-28 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2022-03-31 | 다운그레이드 | Needham | Buy → Hold |
| 2022-03-31 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-29 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-11-14 | 재확인 | Needham | Buy |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-07-11 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-02 | 개시 | JP Morgan | Overweight |
| 2019-03-20 | 개시 | Citigroup | Neutral |
| 2018-09-07 | 재개 | Morgan Stanley | Equal-Weight |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-06-06 | 재확인 | H.C. Wainwright | Buy |
| 2017-12-19 | 개시 | Piper Jaffray | Overweight |
| 2017-12-07 | 개시 | BTIG Research | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | H.C. Wainwright | Buy |
| 2017-04-27 | 재확인 | Needham | Buy |
| 2016-12-27 | 재확인 | H.C. Wainwright | Buy |
| 2016-12-20 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-15 | 개시 | Aegis Capital | Buy |
| 2016-09-29 | 개시 | Brean Capital | Buy |
| 2016-03-16 | 재확인 | Needham | Buy |
| 2016-01-21 | 개시 | Credit Suisse | Neutral |
모두보기
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria
Key facts: Akebia starts Phase 2 trial for Praliciguat; grants stock options - TradingView — Track All Markets
Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat - marketscreener.com
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS) - Yahoo Finance
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Quantisnow
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Finviz
Dow Update: Can Akebia Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Reactions & Accurate Intraday Trade Tips - moha.gov.vn
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Akebia Therapeutics Earnings Notes - Trefis
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Price Targets & Free Safe Capital Growth Stock Tips - Улправда
Why Akebia Therapeutics Inc. (AX9) stock gets analyst attention2025 Performance Recap & Stepwise Trade Signal Implementation - Улправда
What insider trading reveals about Akebia Therapeutics Inc. stockTreasury Yields & Accurate Intraday Trade Tips - Улправда
Is Akebia Therapeutics Inc. stock a buy for dividend growthPrice Action Analysis & Swing Trade Smarter With Data Insights - Bollywood Helpline
Volume Report: Can Akebia Therapeutics Inc. stock outperform in 2025 bull market - Улправда
Why Akebia Therapeutics Inc. stock is a must watch in 2025July 2025 Momentum & Fast Moving Market Watchlists - Улправда
Is Akebia Therapeutics Inc. stock safe for conservative investorsJuly 2025 Price Swings & Stepwise Swing Trade Plans - Улправда
How Akebia Therapeutics Inc. stock performs in weak economyWeekly Trend Summary & Daily Technical Forecast Reports - Улправда
Can Akebia Therapeutics Inc. stock deliver sustainable ROEEarnings Overview Report & Expert Curated Trade Setup Alerts - Улправда
Why Akebia Therapeutics Inc. stock is considered a top pickGlobal Markets & Free Community Supported Trade Ideas - Bölüm Sonu Canavarı
Is Akebia Therapeutics Inc. stock affected by interest rate hikes2025 Retail Activity & Technical Buy Zone Confirmation - DonanımHaber
Is Akebia Therapeutics Inc. (AX9) stock considered safe havenJuly 2025 Spike Watch & Accurate Trade Setup Notifications - DonanımHaber
Why Akebia Therapeutics Inc. (AX9) stock attracts HNW investorsVolume Spike & Weekly Momentum Stock Picks - Улправда
Is Akebia Therapeutics Inc. (AX9) stock a top pick for value investorsMarket Growth Review & Weekly Breakout Stock Alerts - Улправда
Will Akebia Therapeutics Inc. stock remain a Wall Street favoriteJuly 2025 Final Week & Community Consensus Trade Signals - Улправда
Aug Big Picture: Is Akebia Therapeutics Inc. stock safe for conservative investorsGold Moves & Safe Capital Growth Plans - Улправда
Is Akebia Therapeutics Inc. stock a buy on dipsWeekly Profit Recap & Consistent Return Strategy Ideas - Улправда
Activity Recap: What insider trading reveals about Akebia Therapeutics Inc. stockLayoff News & Detailed Earnings Play Alerts - Улправда
Why analysts recommend Akebia Therapeutics Inc. (AX9) stock2025 Earnings Impact & Advanced Swing Trade Entry Plans - ulpravda.ru
Market Moves: Is Akebia Therapeutics Inc. stock a buy on dipsAnalyst Downgrade & Capital Efficiency Focused Ideas - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Akebia Therapeutics (FRA:AX9) OCF Margin % : 47.82% (As of Sep. 2025) - GuruFocus
Akebia Therapeutics announces establishment of rare kidney disease pipeline - MSN
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Why Akebia Therapeutics Inc AX9 stock attracts HNW investorsPortfolio Return Report & Reliable Entry Point Alerts - moha.gov.vn
Will Akebia Therapeutics Inc. (AX9) stock sustain dividend payoutsNew Guidance & Free Technical Pattern Based Buy Signals - Newser
Analysts Offer Insights on Healthcare Companies: NRX Pharmaceuticals (NRXP), Akebia Therapeutics (AKBA) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront - MSN
Is Akebia Therapeutics Inc. (AX9) stock testing key support2025 Key Highlights & Free Real-Time Volume Trigger Notifications - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Akebia Therapeutics, Inc. (AKBA) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Pfizer-backed biotech lands $120M, plus other Boston-area life science news - The Business Journals
Deal Watch: Akebia Gets Phase II Alopecia Areata Candidate From Cost-Conscious Q32 - Citeline News & Insights
Akebia Therapeutics (NASDAQ:AKBA) Receives Buy Rating from BTIG Research - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Akebia Therapeutics Inc (AKBA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.03%
2.38%
자본화:
|
볼륨(24시간):